Independent pharmacies occupy a critical role in community healthcare, providing prescription dispensing, medication therapy management, and increasingly specialty and compounding services that large chain pharmacies cannot easily replicate. The sector faces structural headwinds from PBM reimbursement compression and DIR fees, but independent operators with niche services, loyal patient bases, and long-term care contracts continue to generate stable cash flows attractive to strategic buyers. Consolidation is accelerating as retiring pharmacist-owners seek exits and PE-backed platforms pursue roll-up strategies in specialty and compounding niches.
Who buys these: Independent pharmacy operators, regional pharmacy chains, private equity-backed healthcare platforms, pharmacists seeking ownership, and strategic acquirers looking to expand geographic footprint or add specialty services
3–5.5×
Typical EBITDA multiple
$1M–$5M
Revenue range
Stable
Market trend
SBA Eligible
7(a) financing available
Recession Resistant
Essential service
Buyers typically seek pharmacies with $1M–$5M in revenue, positive EBITDA margins of 8–15%, established customer/patient base with recurring prescription volume, clean DEA and state board compliance history, and ideally a mix of retail and specialty/compounding revenue to buffer PBM reimbursement risk
Get Deal Flow In Your Inbox
New Pharmacy acquisition targets delivered weekly — free to join.
Key items to investigate when evaluating a Pharmacy acquisition
Seller Intelligence
Who sells Pharmacy businesses?
Independent pharmacy owners aged 55–70 approaching retirement, single-location pharmacists facing PBM reimbursement pressure, pharmacy founders looking to exit after building a loyal patient base, and owners of niche pharmacies such as compounding, long-term care, or specialty pharmacies
Typical exit timeline: 12–24 months
Pharmacy businesses in the $1M–$5M revenue range typically sell for 3–5.5× EBITDA. Buyers typically seek pharmacies with $1M–$5M in revenue, positive EBITDA margins of 8–15%, established customer/patient base with recurring prescription volume, clean DEA and state board compliance history, and ideally a mix of retail and specialty/compounding revenue to buffer PBM reimbursement risk
Pharmacy businesses typically trade at 3–5.5× EBITDA in the lower middle market. The market is moderately fragmented with stable demand, which puts pressure on pricing.
Pharmacy businesses are SBA 7(a) eligible, making them accessible to first-time buyers. Asset purchase with prescription file transfer and inventory priced separately at cost
Key due diligence areas include: PBM contract terms, reimbursement rates, and DIR fee exposure; Prescription file value, active patient count, and 30-day refill rate trends; DEA registration, state pharmacy board license transferability, and compliance history; Staff pharmacist and technician retention risk and licensing status; Inventory valuation methodology and accounts receivable aging from third-party payers.
Related Searches
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — all in one place.
Start finding deals — freeNo credit card required
For Buyers
For Sellers